Reaction

Subacute Cutaneous Lupus Erythematosus reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,741 reports · 44 co-occurring drugs

As of the last recalculation, Subacute Cutaneous Lupus Erythematosus appears in 1,741 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is TERBINAFINE HYDROCHLORIDE (PRR 106.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Terbinafine Hydrochloride	76	106.9	107.8
Pemetrexed	57	32.8	32.9
Pemetrexed Disodium	71	23.2	23.2
Hydroxychloroquine	121	20.7	20.8
Travoprost	13	18.1	18.1
Gemcitabine Hydrochloride	63	14.7	14.7
Lansoprazole	195	14.6	14.6
Aprepitant	22	14.4	14.4
Esomeprazole	71	14.2	14.2
Gemcitabine	45	14.0	14.0
Daspone	11	13.6	13.6
Dapsone Gel, 5%	11	13.6	13.6
Fondaparinux Sodium	9	13.4	13.4
Omeprazole	313	13.0	13.0
Telmisartan	19	12.9	12.9
Labetalol	14	12.7	12.7
Dapsone	11	12.4	12.4
Pembrolizumab	103	12.4	12.4
Fosaprepitant Dimeglumine	12	10.5	10.5
Capecitabine	76	10.3	10.3
Anastrozole Tablets	18	10.1	10.1
Omeprazole Magnesium	315	10.1	10.1
Nitrofurantoin	13	9.5	9.5
Nitrofurantoin (Monohydrate/Macrocrystals)	13	9.4	9.4
Ticagrelor	23	8.7	8.7
Fexofenadine	11	8.0	8.0
Diclofenac Potassium	7	7.8	7.8
Carboplatin	79	7.7	7.7
Fluorouracil Cream, 0.5%	48	7.7	7.7
Fluorouracil	48	7.6	7.6
Atezolizumab	23	7.2	7.2
Dofetilide	6	6.8	6.9
Durvalumab	11	6.5	6.5
Pertuzumab	14	6.2	6.2
Osimertinib	16	6.0	6.0
Nivolumab	45	5.7	5.7
Panitumumab	7	5.4	5.4
Oxaliplatin	31	5.1	5.1
Paclitaxel (Aibumin-Bound)	32	4.7	4.7
Paclitaxel	38	4.7	4.7
Obinutuzumab	6	4.4	4.4
Belimumab	11	4.2	4.2
Encorafenib	3	3.6	3.6
Palbociclib	27	3.4	3.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.